Xenon Pharmaceuticals has reported a fourth-quarter loss of $3.9 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 27 cents.
The gene therapy biotech company posted revenue of $3.2 million in the period.
Read: Valeant interim CEO vows to regain investor trust by delivering growth
For the year, the company reported a loss of $15.8 million, or $1.10 per share, swinging to a loss in the period. Revenue was reported as $15.6 million.
Xenon Pharmaceuticals shares have declined almost 9% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.33, a decline of 61% in the last 12 months.
Read: Working group formed to tackle national pharmaceutical strategy